Deferred Tax Assets, Valuation Allowance of CRISPR Therapeutics AG from 31 Dec 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
CRISPR Therapeutics AG quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2015 to 31 Dec 2025.
  • CRISPR Therapeutics AG Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $345,395,000, a 22% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

CRISPR Therapeutics AG Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $345,395,000 +$62,656,000 +22% 31 Dec 2025 10-K 12 Feb 2026 2025 FY
Q4 2024 $282,739,000 +$55,124,000 +24% 31 Dec 2024 10-K 12 Feb 2026 2025 FY
Q4 2023 $227,615,000 +$29,336,000 +15% 31 Dec 2023 10-K 11 Feb 2025 2024 FY
Q4 2022 $198,279,000 +$99,630,000 +101% 31 Dec 2022 10-K 21 Feb 2024 2023 FY
Q4 2021 $98,649,000 -$17,991,000 -15% 31 Dec 2021 10-K 21 Feb 2023 2022 FY
Q4 2020 $116,640,000 +$70,727,000 +154% 31 Dec 2020 10-K 15 Feb 2022 2021 FY
Q4 2019 $45,913,000 +$9,705,000 +27% 31 Dec 2019 10-K 16 Feb 2021 2020 FY
Q4 2018 $36,208,000 +$23,167,000 +178% 31 Dec 2018 10-K 12 Feb 2020 2019 FY
Q4 2017 $13,041,000 +$6,271,000 +93% 31 Dec 2017 10-K 25 Feb 2019 2018 FY
Q4 2016 $6,770,000 +$3,878,000 +134% 31 Dec 2016 10-K 08 Mar 2018 2017 FY
Q4 2015 $2,892,000 31 Dec 2015 10-K 10 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.